

**Amendments To The Claims**

1-14. (Canceled)

15. (Currently amended) A method for treating an SSTR-associated disorder in a mammalian subject, the method comprising administering to the subject a composition comprising a somatostatin analog of the formula:

(A – B)

wherein:

A is ~~eysteine, or~~ a peptide chain comprising one or more cysteine residues, ~~wherein a therapeutic agent is bound to the one or more~~  
~~eysteine residues via a thiol linkage; and~~

B is a naturally occurring or synthetic somatostatin peptide, or fragment thereof, which binds to a somatostatin receptor; ~~and~~

wherein a therapeutic agent is bound to the somatostatin analog (A – B) via a thiol linkage to the one or more cysteine residues of (A) at an interior site(s);

whereby a SSTR-associated disorder is treated.

16. (Original) The method of claim 15, wherein A comprises the peptide sequence of any one of SEQ ID NOs:1-3, or wherein A is a single cysteine residue.

17. (Original) The method of claim 15, wherein B comprises SEQ ID NO:4.

18. (Original) The method of claim 15, wherein the somatostatin analog comprises a peptide of any one of SEQ ID NOs:5-7.

19. (Original) The method of claim 15, wherein the therapeutic agent is selected from the group consisting of a radioisotope, a cytotoxin, an immunostimulatory agent, an anti-angiogenic agent, a therapeutic gene, and a chemotherapeutic agent.

20. (Original) The method of claim 15, wherein the SSTR-associated disorder is cancer.